

Resource Summary Report

Generated by [RRID](#) on Aug 27, 2026

HuT 78

RRID:CVCL_0337

Type: Cell Line

Proper Citation

RRID:CVCL_0337

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0337

Proper Citation: RRID:CVCL_0337

Description: Cell line HuT 78 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Sezary syndrome

Defining Citation: [PMID:2144611](#), [PMID:2193399](#), [PMID:2567177](#), [PMID:2985879](#), [PMID:3159941](#), [PMID:3495441](#), [PMID:3874327](#), [PMID:6151082](#), [PMID:6244013](#), [PMID:6954533](#), [PMID:6975346](#), [PMID:7707540](#), [PMID:8127147](#), [PMID:8806089](#), [PMID:8806090](#), [PMID:8806092](#), [PMID:9738977](#), [PMID:10570904](#), [PMID:11416159](#), [PMID:12068308](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:25355872](#), [PMID:25877200](#), [PMID:30285677](#), [PMID:30894373](#), [PMID:31068700](#)

Comments: Anecdotal: For a number of years it was not known that H9 used by Gallo's lab to isolate HIV-1 (HTLV-III) was in fact a clone of Hut 78 from Minna's lab (PubMed=2567177). This created a controversy between the labs of Minna and Gallo (PubMed=2193399)., Population: Caucasian., Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981)., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HuT 78

Synonyms: Hut 78, HUT 78, HuT-78, HUT-78, HuT78, Hut78, HUT78, NCI-H78

Cross References: BTO:BTO_0001945, CLO:CLO_0004304, CLO:CLO_0051010, EFO:EFO_0002209, MCCL:MCC:0000233, CLDB:cl1778, CLDB:cl1779, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2770, ATCC:CRM-TIB-161, ATCC:TIB-161, BCRC:60522, BCRJ:0370, BEI_Resources:ARP-89, BioSample:SAMN01821566, BioSample:SAMN03471940, BioSample:SAMN03473203, BioSample:SAMN10987600, cancercellines:CVCL_0337, CCRID:1101HUM-PUMC000190, CCRID:3101HUMTCHu206, CCTCC:GDC0307, Cell_Model_Passport:SIDM00851, CGH-DB:9026-4, ChEMBL-Cells:ChEMBL3307500, ChEMBL-Targets:ChEMBL613978, CLS:300338, Cosmic:724829, Cosmic:1551450, Cosmic:2153070, Cosmic:2402468, Cosmic:2765583, DepMap:ACH-000509, ECACC:88041901, GEO:GSM887154, GEO:GSM888226, GEO:GSM1374569, IARC_TP53:185, IGRhCellID:HuT78, KCLB:90078, LiGeA:CCLE_696, LINCS_LDP:LCL-2005, Lonza:813, NCBI_Iran:C185, PharmacDB:HuT78_647_2019, Progenetix:CVCL_0337, PubChem_Cell_line:CVCL_0337, RCB:RCB1934, TKG:TKG 0375, TOKU-E:1977, Wikidata:Q54896909

ID: CVCL_0337

Record Creation Time: 20220427T220623+0000

Record Last Update: 20260815T234300+0000

Ratings and Alerts

No rating or validation information has been found for HuT 78.

No alerts have been found for HuT 78.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 284 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Ianevski A, et al. (2026) Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery. Cancer research, 86(2), 295.

Tang A, et al. (2026) Targeting BCMA in multiple myeloma with a trifunctional NK cell engager. Cell reports. Medicine, 7(3), 102628.

Yagüe-Capilla M, et al. (2026) IMPDH inhibition enhances cytarabine efficacy in SAMHD1-expressing leukaemia cells via guanine nucleotide depletion. Molecular oncology.

He L, et al. (2026) SATB1 regulates TXNIP inhibiting invasion and infiltration in T-cell acute lymphoblastic leukemia. Cancer gene therapy, 33(1), 55.

Martínez Villarreal A, et al. (2025) Memory T-Cell Phenotype in Cutaneous T-Cell Lymphoma Is Modified by Germline Gene Gametocyte Specific Factor 1. *Experimental dermatology*, 34(5), e70123.

Jeong Y, et al. (2025) Dual targeting of EZH2 and PD-L1 in Burkitt's lymphoma enhances immune activation and induces apoptotic pathway. *Frontiers in immunology*, 16, 1578665.

Webb L, et al. (2025) Membrane-bound IL-15 co-expression powers a potent and persistent CD70-targeted TRuC T-cell therapy. *Frontiers in immunology*, 16, 1609658.

Robey RW, et al. (2024) The Methyltransferases METTL7A and METTL7B Confer Resistance to Thiol-Based Histone Deacetylase Inhibitors. *Molecular cancer therapeutics*, 23(4), 464.

Rink JS, et al. (2024) Encapsulation and Delivery of the Kinase Inhibitor PIK-75 by Organic Core High-Density Lipoprotein-Like Nanoparticles Targeting Scavenger Receptor Class B Type 1. *ACS applied materials & interfaces*.

Ogishi M, et al. (2024) Impaired development of memory B cells and antibody responses in humans and mice deficient in PD-1 signaling. *Immunity*, 57(12), 2790.

Ward GA, et al. (2024) Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma. *Cancer research communications*, 4(6), 1441.

Chu X, et al. (2023) Human Antibody VH Domains Targeting GPNMB and VCAM-1 as Candidate Therapeutics for Cancers. *Molecular pharmaceuticals*, 20(5), 2754.

Chen O, et al. (2023) Mechanisms and treatments of neuropathic itch in a mouse model of lymphoma. *The Journal of clinical investigation*, 133(4).

Merk-Ahmad K, et al. (2023) The RHOA Mutation G17V Does Not Lead to Increased Migration of Human Malignant T Cells but Is Associated with Matrix Remodelling. *Cancers*, 15(12).

Ropio J, et al. (2023) Spotlight on hTERT Complex Regulation in Cutaneous T-Cell Lymphomas. *Genes*, 14(2).

Polakowski N, et al. (2023) HBZ upregulates myoferlin expression to facilitate HTLV-1 infection. *PLoS pathogens*, 19(2), e1011202.

Krstulović L, et al. (2023) Novel 7-Chloro-4-aminoquinoline-benzimidazole Hybrids as Inhibitors of Cancer Cells Growth: Synthesis, Antiproliferative Activity, in Silico ADME Predictions, and Docking. *Molecules (Basel, Switzerland)*, 28(2).

Liu H, et al. (2023) Strategic self-limiting production of infectious HIV particles by CRISPR in permissive cells. *Molecular therapy. Nucleic acids*, 32, 1010.

Otte M, et al. (2023) The miR-141/200c-STAT4 Axis Contributes to Leukemogenesis by Enhancing Cell Proliferation in T-PLL. *Cancers*, 15(9).

Ernzen K, et al. (2023) The PRMT5 inhibitor EPZ015666 is effective against HTLV-1-transformed T-cell lines in vitro and in vivo. *Frontiers in microbiology*, 14, 1101544.